First description of a sporadic breast cancer in a woman with BRCA1 germline mutation
Metrics: PDF 667 views | HTML 1140 views | ?
Elsa Curtit1,2,3,4,9, Vanessa Benhamo5, Nadège Gruel6,7, Tatiana Popova6, Elodie Manie6, Paul Cottu1, Odette Mariani8, Dominique Stoppa-Lyonnet8, Xavier Pivot2,3,4, Marc-Henri Stern6, Anne Vincent-Salomon5,8
1Department of Medical Oncology, Institut Curie, 75248 Paris, France
2Department of Medical Oncology, University Hospital, 25000 Besançon, France
3University of Franche-Comté, Medical Department, 25000 Besançon, France
4INSERM U1098, Medical Oncology Department, 25000 Besançon, France
5Université Paris Sciences Lettres, Medical Department, INSERM U934, Institut Curie, 75248 Paris, France
6Université Paris Sciences Lettres, Medical Department, INSERM U830, Institut Curie, 75248 Paris, France
7Department of Translational Research, Institut Curie, 75248 Paris, France
8Department of Pathology, Genetics and Immunology, Institut Curie, 75248 Paris, France
9Present affiliations: 2–4; affiliation when working on this case: 1
Elsa Curtit, e-mail: email@example.com
Keywords: breast cancer, BRCA1, HER2, sequencing
Received: June 22, 2015 Accepted: September 17, 2015 Published: September 29, 2015
We describe the case of a woman carrying a germline pathogenic BRCA1 mutation diagnosed with a breast cancer overexpressing HER2. Clinical presentation of the tumor, HER2-positivity, genomic profile and loss of the mutated BRCA1 allele in tumor evidence that BRCA1 is not inactivated in this breast cancer. It represents the first biological demonstration for the existence of a sporadic HER2-positive breast cancer independent from BRCA loss of function in a woman carrier of a deleterious BRCA1 mutation. In a context where targeted therapies based on BRCA loss of function in the tumor are developed, such case could have direct implications.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.